Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Ushering in a New Era of Sustainable Weight Loss With Incretin-Based Therapies
  • CME
  • CE

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: July 26, 2021 Expiration: July 25, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.
Randy J. Seeley, PhD
Jenny Tong, MD, MPH
Kristina M. Utzschneider, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Examine the metabolic adaptations that contribute to weight loss challenges in patients with obesity
  • Describe the physiologic and metabolic effects of incretin-based therapies that lead to weight loss in patients with obesity and the benefits of sustained weight loss on obesity-related comorbidities
  • Summarize the long-term efficacy and safety data of current and emerging incretin-based therapies for the treatment of patients with obesity

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Randy J. Seeley, PhD

H.K. Ransom Professor of Surgery
Internal Medicine and Nutritional Sciences
Director, Michigan Nutrition Obesity Research Center
University of Michigan
Ann Arbor, Michigan

Randy J. Seeley, PhD, has disclosed that he has received funds for research support from AstraZeneca, Ionis, Kintai, and Novo Nordisk; has received consulting fees from Ionis, Kintai, Lilly, Novo Nordisk, and Scohia; and has ownership interest in Calibrate and Rewind.
Jenny Tong, MD, MPH

Associate Professor
Division of Metabolism, Endocrinology and Nutrition
University of Washington
VA Puget Sound Health Care Systems
Seattle, Washington

Jenny Tong, MD, MPH, has no relevant conflicts of interest to report.
Kristina M. Utzschneider, MD

Assistant Professor, Medicine
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, Washington

Kristina M. Utzschneider, MD, has disclosed that she has received funds for research support from Avid and Lilly.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The online activities are intended to meet the educational needs of endocrinologists (physicians and fellows), internists, primary care physicians, endocrine nurses, pharmacists, and other advanced practice professionals who care for individuals with obesity.

Goal

The goals of this program are to improve healthcare professionals’ understanding of:

  • The metabolic adaptation in obesity
  • The value of sustained weight loss and related complications
  • The latest evidence for incretin-based therapies for long-term weight management

 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.5 contact hour (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-135-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 26, 2021, through July 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Ushering in a New Era of Sustainable Weight Loss With Incretin-Based Therapies
  • CME
  • CE

Loading...
Learn about the metabolic adaptations in obesity, the value of sustained weight loss, and the latest evidence for incretin-based therapies for long-term weight management.
Randy J. Seeley, PhD
Jenny Tong, MD, MPH
Kristina M. Utzschneider, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: July 26, 2021 Expiration: July 25, 2022

Related Content

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on emerging data on tirzepatide for type 2 diabetes

Carol Hatch Wysham, MD Released: September 21, 2021

Downloadable slides from Clinical Care Options (CCO) featuring expert insights on the clinical trial data supporting the use of tirzepatide in T2D

Carol Hatch Wysham, MD Released: September 2, 2021

Short video from Clinical Care Options (CCO) featuring expert insights on the clinical trial data supporting the use of tirzepatide in T2D

Carol Hatch Wysham, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Dieticians/Dietetic Technicians, Registered: maximum of 0.25 CPEU(s) Released: September 2, 2021 Expired: September 1, 2022

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on the role of obesity in the pathogenesis of type 2 diabetes

Carol Hatch Wysham, MD Released: September 2, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue